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Abstract Background and Aim:Acetylsalicylic acid (ASA [aspirin]) is a commonly used
over-the-counter drug for the treatment of pain, fever, or colds, but data on
the safety of this use are very limited. The aim of this study was to provide
data on the safety of this treatment pattern, which is of interest to clinicians,
regulators, and the public.
Methods: A meta-analysis of individual patient data from 67 studies spon-
sored by Bayer HealthCare was completed. The primary endpoints were
patient-reported gastrointestinal (GI) adverse events (AEs); the secondary
endpoints were the incidence of patient-reported non-GI AEs. Event in-
cidence and odds ratios (ORs) based on Cochran-Mantel-Haenszel estimates
are reported. In total, 6181 patients were treated with ASA, 3515 with pla-
cebo, 1145 with acetaminophen (paracetamol), and 754 with ibuprofen. Ex-
posure to ASA was short term (82.5% of patients had a single dose).
Results: GI AEs were more frequent with ASA (9.9%) than with placebo
(9.0%) [OR 1.3; 95% CI 1.1, 1.5]. Dyspeptic symptoms were infrequent (4.6%
in placebo subjects). The ORs for ASA were 1.3 (95% CI 1.1, 1.6) versus
placebo; 1.55 (95% CI 0.7, 3.3) versus ibuprofen; and 1.04 (95% CI 0.8, 1.4)
versus acetaminophen. There were very few serious GI AEs (one ASA case;
three placebo cases). No differences were found for non-GI AEs and no cases
of cerebral hemorrhage were reported.
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Conclusion: Short-term, mostly single-dose exposure to ASA for the treatment
of pain, fever, or colds was associated with a small but significant increase in the
risk of dyspepsia relative to placebo. No seriousGI complications were reported.
Background
Acetylsalicylic acid (ASA [aspirin]) at doses of
£325mg/day is used for the treatment and preven-
tion of cardiovascular events.[1] At higher doses,
used for the treatment of pain, fever, or colds, it is
one of the most commonly used over-the-counter
(OTC) drugs worldwide.[2] The recommendedOTC
dose for these indications varies by country, but is
generally 500–1000mg as a single dose and 3000–
4000mg/day. Marketing surveys indicate that
treatment is usually short term for acute pain, sug-
gesting that most people take one to two tablets
for 1 day.[3]
At these doses, ASA can be considered a tra-
ditional nonselective NSAID.[4] These compounds
are associated with an increased risk of side ef-
fects, and those in the gastrointestinal (GI) tract
are among the most frequently reported.[5] GI
complications are life-threatening events asso-
ciated with NSAID use, but other adverse effects
such as dyspepsia are also important since they
may lead to avoidance of treatment.[5,6]
There are only limited data on GI safety re-
garding short-term ASA use for the treatment of
various acute conditions. Observational studies
have reported the relative risks of upper GI bleed-
ing associated with ASA above 500mg/day to be
similar to those of other NSAIDs, but informa-
tion on dose, duration of treatment, type of use,
and indication is often limited or absent. Ob-
servational studies often do not differentiate be-
tween chronic and acute OTCASA use or they do
not capture OTC use at all, severely limiting the
interpretation of the data.[7-9] Moreover, data re-
garding more frequent GI side effects associated
with NSAID use such as dyspepsia are rarely re-
ported in the literature.[10] Data on doses of ASA
used for the treatment of pain, fever, or colds have
been even less frequently reported.
Other side effects associated with ASA use in-
clude intracranial bleeding, other non-GI bleed-
ing, tinnitus, dizziness, headache, impaired hearing,
hypersensitivity reactions, andmental confusion.[11]
Data on the occurrence of these side effects dur-
ing short-term ASA use for acute conditions have
rarely been reported.
To investigate these adverse events (AEs), we
evaluated the safety profile of short-term ASA
use at the recommended doses for various OTC
ASA indications, based on individual subject data
obtained from all clinical trials with doses of ASA
‡325mg/day conducted by Bayer HealthCare
between 1987 and 2008.
Methods
Setting
Individual patient data for the meta-analysis
were obtained from all studies conducted by
Bayer HealthCare by 31March 2008, where ASA
was evaluated in a clinical trial setting and where
adequate data documentation in terms of AE
reporting was available. The data pool contained
87 studies in total. Among these, 33 were double-
blind, 2 were single-blind, 31 were open-label, and
the blinding in one study was not recorded. All
studies included were either efficacy or pharma-
cokinetic studies. Studies of low-dose ASA for
the prevention of cardiovascular diseases (daily
dose £325mg) were excluded. As a result, data
from 67 studies were considered for this report.
The most relevant inclusion criteria in these
studies were as follows: (i) patient presented with
the investigated indication in pain, fever, or colds,
and was otherwise healthy (efficacy study); and
(ii) volunteers (pharmacokinetic studies). The
most relevant exclusion criteria were as follows:
(i) history of presence of asthma or hypersensitivity
to ASA, salicylate, or NSAIDs; (ii) active peptic
ulcer; (iii) history of gastroduodenal bleeding;
(iv) hemorrhagic diathesis; (v) impaired hepatic
function; or (vi) impaired renal function.
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Endpoints
The primary endpoints were patient-reported
GI AEs. During the studies, trial subjects were
asked to report any AE, investigators were in-
structed to provide clinical diagnosis of AEs when
possible, and Bayer HealthCare assigned the ap-
propriate Medical Dictionary for Regulatory Ac-
tivities (MedDRA) term to each AE. MedDRA
codes (version 11.0) were used for the identifica-
tion of AEs of interest in all clinical trials in the
database, either according to predefined, stand-
ardized MedDRA queries or according to se-
lected MedDRA preferred terms, high-level terms,
high-level group terms, or system organ classes.
The four academic authors (AL, DM, SS, JB) de-
fined a priori the choice of terms for appropriate
retrieval of these events; the same authors also
defined the additional events of interest for the
so-called combined preferred terms per system
organ class. GI preferred terms were combined
into the following variables: GI bleeding, dyspepsia,
severe dyspepsia, minor dyspepsia, severe dyspep-
sia, any dyspepsia, abdominal pain, GI bleeding,
gastroesophageal reflux disease (GERD)-related
symptoms. Definitions of these combined pre-
ferred terms are included in table I.
Secondary endpoints were patient-reported non-
GI AEs, including cerebral hemorrhage, other
bleeding (non-GI, non-cerebral), hypersensitivity
reactions, headache, dizziness, impaired hearing
ability, tinnitus, mental confusion, oral compli-
cations and ‘signs of overdose’ as a composite of
the following AEs of interest: headache, dizziness,
impaired hearing ability, tinnitus, and mental
confusion. MedDRA codes were also used for
identification of these AEs of interest. For both
primary and secondary endpoints, a time window
of 7 days after drug discontinuation was used to
include events from any treatment arm that were
defined as ‘treatment related.’
Treatments Considered for the Analysis
Clinical trials in the Bayer HealthCare data-
base that studied treatment with ASA alone and
in combination with another active ingredient
(pseudoephedrine, lidocaine, or dextromethor-
phan) versus placebo or active comparator. For
the purpose of this analysis, combinations of
ASA plus vitamin C, ASA plus caffeine, andASA
plus calcium were considered to be ‘ASA alone.’
This study reports on comparisons between two
different treatment arms: ASA versus placebo,
each given alone or each combined with addi-
tional therapy (e.g. pseudoephedrine, lidocaine,
or dextromethorphan). In addition, some studies
were an ‘active comparator.’ These were acet-
aminophen (paracetamol), carried out comparing
ASA with ibuprofen, pseudoephedrine, suma-
triptan, lidocaine, ketoprofen, or, in a few cases,
ergotamine tartrate and ASA-acetaminophen-
caffeine combinations. We report events from
Table I. Definitions of gastrointestinal (GI) combined preferred
terms (PTs)
Combined PT Included PTs
Dyspepsia Dyspepsia
Epigastric discomfort
Eructation
Minor dyspepsia Abdominal discomfort
Dyspepsia
Epigastric discomfort
Eructation
Flatulence
Gastric dilatation
Gastric disorder
Hyperchlorhydria
Nausea
Stomach discomfort
Abdominal pain upper
Severe dyspepsia Retching
Vomiting
Any dyspepsia Included PTs for ‘Minor dyspepsia’
and ‘Severe dyspepsia’ combined
Abdominal pain Abdominal pain
Abdominal pain lower
GI bleeding Haematemesis
Haematochezia
Melaena
GERD-related symptoms Gastrooesophageal reflux disease
Dysphagia
Oesophageal pain
Salivary hypersecretion
GERD = gastroesophageal reflux disease.
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studies comparing ASA with either acetamino-
phen or ibuprofen, since only clinical trials with
these compounds are of major clinical interest
and only these studies had a sufficient number of
cases to carry out appropriate analyses.
Data Extraction and Management
Data management and statistical evaluation
was performed using the SAS software package
version 9.2 (SAS Institute Inc., Cary, NC, USA).
The database structure was developed between
Bayer HealthCare and M.A.R.C.O., Dusseldorf,
Germany, an independent institute for clinical re-
search and statistics. Data were provided by Bayer
HealthCare in one of the following formats: data
listings derived from medical research reports on
paper, data listings frommedical research reports
in PDF, or SAS datasets. Data listings provided
as paper copies were entered into the database,
either by independent double-data entry with
subsequent comparison of the datasets and entry-
error correction, or, in case of small studies with
few data, by single data entry with a subsequent
100% visual inspection. Data listings provided in
PDFwere copied intoMicrosoft Excel (Microsoft
Corporation, Redmond,WA, USA) and then im-
ported into SAS. The SAS datasets were then
transformed into the target database structure
using SAS modification programs. Information
derived from the medical research reports con-
cerning study title, design, blinding, randomiza-
tion, dosing, and so forth was integrated into the
target database. Appropriate quality control checks
were in place at each data management step.
Statistics
The scope of the analysis, statistical methods,
and content of tables and graphs was docu-
mented and pre-specified in a statistical analysis
plan (SAP) by all authors prior to start of the
analysis. We have estimated incidence rates for
both AEs overall and those events specified by
the trial investigators as adverse drug related (i.e.
adverse drug reactions [ADRs]). All statistical anal-
yses were descriptive in nature. Incidence rates
calculated for this meta-analysis refer to the num-
ber of subjects who reported at least one event in
the numerator and the number of all subjects
under observation in the denominator.
Measures of Treatment Effect
Analysis of risk differences and odds ratios
(ORs) were performed for all events of interest
and treatment comparisons defined in the Treat-
ments Considered for the Analysis section. In all
analyses, trial was used as a stratum, as is stan-
dard in meta-analysis.[12,13] These analyses were
performed twice, excluding and including studies
with no AEs (‘zero-event studies’) in both treat-
ment arms and for all reported AEs, as well as
drug-related AEs, yielding a total of 1280 analyses.
Confidence interval plots (forest plots) and radial
plots (Galbraith plots) were provided for the risk
analyses. Estimated ORs and risk differences were
based on Cochran-Mantel-Haenszel estimates, as
this is robust even in ‘sparse data’ stratifications
(i.e. where few cases of AEs occur). Weighted
estimates for ORs and risk differences were cal-
culated[14-16] and reported. For handling of zero-
event studies, a standardized continuity correction
of 0.05 was used, taking into account the size of
treatment arms.[16] This was a deviation from the
SAP, where a factor of 1/10000 was proposed.
For analysis of heterogeneity over studies, a
modified Breslow-Day statistic was used in the OR
analyses[17,18] and the Cochran-Mantel-Haenszel
Q-statistic was used in the risk difference analy-
ses.[19] A p-value of 0.10 was considered to in-
dicate heterogeneity.
Assessment of ASA-by-subgroup interactions
was carried out for sex and age. For each event of
interest, a Cochran-Mantel-Haenszel risk analysis
was performed and the OR for the comparisons
was estimated separately between male and fe-
male subjects. The two estimates were then com-
pared and the difference calculated (log OR [ASA
vs placebo for male patients] minus log OR [ASA
vs placebo for female patients]). The variance of
this contrast was calculated as the sum of the
variances of the two log ORs. The square root of
this was taken as the standard error and used to
calculate 95% confidence intervals. The test sta-
tistic for interaction was the ratio of this difference
to its standard error.[20] Analogously, estimates
for the ASA-by-age interaction were derived.
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Two different subgroup allocations were consid-
ered: patients <40 versus patients ‡40 years of age
and patients <65 versus patients ‡65 years of age.
Subgroup analyses concerning daily dose, treat-
ment duration, and treatment formulation were
also performed. A p-value of <0.10 was assumed
to provide evidence of heterogeneity.
Both treatment arms were included for parallel-
group studies; only data from the first period
were included for crossover studies. Descriptive,
exploratory evaluations, and statistical analyses
were based on available data. AEs with incom-
plete or missing onset dates were considered as
treatment related. The same approach was also
used if no dosing date was given.
All patients treated at least once were included
in the analysis. For the subgroup analyses, pa-
tients were grouped according to combinations of
treatment duration (single dose, multiple dose,
all) and formulation (plain: tablets, coated tablets,
capsules, dry granules; effervescent tablets; intra-
venous; all). Multiple dosing was defined as more
than one dose of study drug in any of the treat-
ment groups.
Results
Description of Trials and Demographics
of Patients
A total of 67 studies were included in the
analysis (figure 1). The aim of the majority of the
studies included was the evaluation of the efficacy
of ASA for the treatment of pain, fever, or colds;
a small number were conducted to evaluate the
pharmacokinetics of ASA. Overall, exposure to
Meta-analysis of individual patients' data
(67 studies) 
Design
  parallel-group (n = 30)
  crossover (n = 37)
Countries
  Europe (n = 35)
  US (n = 13)
  Japan (n = 1)
Blindness
  double-blind (n = 33)
  open-label (n = 31)
  single-blind (n = 2)
  unrecorded
  blinded status (n = 1)
Centers
  single-center (n = 47)
  multicenter (n = 20)
Clinical phase
  I (n = 38)
  II (n = 2)
  III (n = 16)
  IV (n = 10)
  unknown (n = 1)
Study characteristics 13 222 patients
Parallel design (n = 12 177)
Crossover design (n = 1045)
Indication
  pain (n = 5650)
  cold (n = 5742)
  kinetics (n = 1812)
ASA
(n = 6181)
Placebo
(n = 3515)
Active comparator
(n = 3526)
Paracetamol
(n = 1145)
Ibuprofen
(n = 754)
Other
(n = 1627)
Plain
(n = 3724)
Effervescent
(n = 2298)
IV (n = 159)
Fig. 1. Summary of the type of studies included in the meta-analysis and the distribution of patients by treatment. ASA = acetylsalicylic acid
(aspirin); IV = intravenous.
Short-Term ASA Use and GI AEs 281
ª 2011 Lanas et al., publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (3)
ASA and its combinations was brief. Of the 6181
patients allocated to ASA and ASA combinations,
5099 (82.5%) received a single dose, 1082 (17.5%)
received a multiple-dose regimen, and 188 (3.0%)
were treated for more than 5 days. Over half (54%;
3337 patients) of the ASA study population took
a daily dose between 500 and 1000mg (figure 2).
The daily doses of acetaminophen taken by pa-
tients in these trials were 300mg (31%), 500mg
(16.6%), and 1000mg (52.3%), whereas the doses
of ibuprofen were 200mg (45%) and 400mg
(55%). The demographics of patients are included
in table II.
Safety Analysis
The overall incidence of AEs was low, and was
similar between subjects treated with ASA (741/
4884; 15.2%) and those treated with placebo (580/
3731; 15.5%) [OR 1.1; 95% CI 0.96, 1.2]; risk dif-
ference 1.0% (95 % CI -0.5, 2.5). GI AEs of any
severity were more frequent in the ASA groups
than in the placebo groups, as summarized in
table III. Risks of abdominal pain and GERD-
related symptoms were non-significantly increased
in the ASA groups; severe dyspepsia was non-
significantly less common in ASA subjects. There
were very few serious GI adverse events; one case
of acute appendicitis in the ASA plus pseudo-
ephedrine arm and two cases in the placebo arm
(one hematemesis and one appendicitis perfo-
ration). Neither the appendicitis nor the appen-
dicitis perforation events were considered drug
related by the original study investigators. GI hem-
orrhage (hematemesis) was reported once among
subjects randomized to ASA plus dextromethor-
phan and three times among subjects randomized
to placebo (hematemesis, hematochezia, and me-
lena). Similar figures were observed when events
were analyzed as drug-related AEs, although
absolute numbers were smaller (figure 3).
No cerebral hemorrhage or hypersensitivity
reaction occurred in any of the trials, although
one occurrence of impaired hearing ability and
another of mental confusion were reported in the
ASA groups. Other non-GI AEs are also sum-
marized in table III. There was a reduction in the
risk of headache from ASA and there were non-
significant increases in tinnitus and non-GI bleed-
ing. Very similar results to those reported in table III
were obtained when ASA in monotherapy was
compared with placebo alone (data not shown).[21]
There was no indication of heterogeneity across
studies in AEs for the OR analysis; there was
statistically significant heterogeneity in the risk
difference analysis for the terms GI AE, dyspep-
sia, minor dyspepsia, any dyspepsia, headache,
signs of overdose, and oral complications. Since
60
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33.1
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2.0 3.6 1.6
5.4
0.0 0.3
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00
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00
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00
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00
>2
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0−
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00
>3
00
0−
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>3
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0−
40
00
Median daily dose (mg)
Fig. 2. Range of daily dose of acetylsalicylic acid (aspirin) taken by patients in the trials and the proportion of patients for each dose range.
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ORs were considered to be the main parameter,
no steps were undertaken to correct for statistical
heterogeneity in this analysis of pooled data.
Additional analyses were made according to
ASA formulation, median daily ASA dose, and
single- versus multiple-dose regimens. Overall,
compared with plain and effervescent oral for-
mulations, the incidence of AEs with exposure to
intravenous ASA was lower (data not shown).[21]
More patients receiving doses >1000mg/day re-
ported AEs (18.1%) than those receiving doses
<500mg/day (15.1%) or those receiving placebo
(13.5%). Multiple-dose administration of ASA
(up to 5 days) was associated with an increased
incidence of AEs (16.2%) when compared with
single-dose administration (12.8%), and this was
similar to results observed in the placebo arm
(17.0% and 12.8%, respectively).
Acetylsalicylic acid (ASA [Aspirin])-by-
Subgroup Interaction
Analyses for detection of an interaction between
age (<65 vs ‡65 years of age; <40 vs ‡40 years of
age) or sex (male vs female) and the risk of ex-
periencing an AE were carried out for the com-
parison of ASA versus placebo. There was no
interaction by age or sex for any of the events of
interest. For the combined term ‘minor dyspep-
sia’, a borderline statistically significant (p= 0.052)
interaction effect was observed for patients
‡40 years of age when compared with those
<40 years of age (OR 1.98 [95% CI 1.2, 3.1]).
Approximately 1% of the patients were ‡65 years
old (1.1% of patients on ASA, 1.3% of patients on
placebo) and therefore no meaningful data can be
reported for these subgroups.
Table II. Characteristics of subjects included in the meta-analysis
Parameter Placebo All acetylsalicylic acid
(aspirin) treatments
Active comparator Total
Sex [n (%)]
Men 1257 (36) 2638 (43) 1260 (36) 5155 (39)
Women 2258 (64) 3543 (57) 2266 (64) 8067 (61)
Race/ethnicity [n (%)]
Unknown 314 (9) 916 (15) 955 (27) 2185 (17)
Caucasian 2917 (83) 4843 (78) 2351 (67) 10 111 (76)
Black 146 (4) 217 (4) 103 (3) 466 (4)
Asian 27 (1) 41 (1) 20 (1) 88 (1)
Hispanic 74 (2) 93 (2) 51 (1) 218 (2)
Other 37 (1) 71 (1) 46 (1) 154 (1)
Age [y]
n 3465 6131 3276 12 872
Mean 33.22 32.51 33.30 32.9
SD 12.92 12.67 13.28 12.9
Range 15–77 15–81 15–78 15–81
Weight [kg]
n 3463 6088 3275 12 826
Mean 71.31 72.31 72.16 72.00
SD 14.98 15.14 15.29 15.14
Range 40–158 35–167 37–159 35–167
BMI [kg/m2]
n 3463 6088 3274 12 825
Mean 24.65 24.71 24.90 24.74
SD 4.50 4.58 4.64 4.57
Range 12.5–56.2 14.5–60.6 15.4–60.1 12.5–60.6
BMI = body mass index.
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ASA versus Active Comparator
This analysis was carried out comparing ASA
monotherapy (all doses) with acetaminophen
(300–1000mg/day) or ibuprofen (200–400mg/day).
Table IV summarizes the rates and ORs for the
different GI and non-GI AEs. In general, the rates
were low for all AEs. No statistically significant
differences for the combined terms of dyspepsia
were found between treatments, although the
ORs were >1.0 for the comparisons with ibupro-
fen. Similar figures were observed when data
were reported as ADRs (data not shown).[21]
Discussion
This meta-analysis has shown that the risk of
AEs from ASA was low at the doses and dura-
tions commonly consumed as OTC medication
for the relief of pain, fever, or colds. In particular,
there was a virtual absence of major GI (e.g. bleed-
ing or perforation) and non-GI complications (e.g.
cerebral hemorrhage). The use of ASA was as-
sociated with a small increase of the risk of dys-
pepsia when compared with placebo and with a
non-significant increase in comparison with ibu-
profen, another OTC drug also commonly used
for the treatment of colds or acute pain. There was
an increased risk of dyspepsia with ASA versus
acetaminophen when considering the ‘dyspepsia’
MedDRA term, but not when the broader,
combined dyspepsia terms defined a priori by the
academic authors were used (table I).
It is important to emphasize that the conclusions
obtained from this study on the safety of this ther-
apeutic approach with ASA apply only to very
short-term treatment. The majority of patients
included in these trials took a single dose of
500–1000mg in 1 day and were relatively young.
Nonetheless, the data reported are clinically valu-
able. First, previous information on the safety of
ASA at OTC doses has relied on a small num-
ber of observational studies, since many inves-
tigations do not report on OTC use. Second, the
Table III. Gastrointestinal (GI) adverse events (AEs) and non-GI AEs occurring in patients treated with acetylsalicylic acid (ASA [aspirin]) or
placebo
Event ASA arm [%] (n= 4884) Placebo arm [%] (n =3731) OR (95% CI) Risk difference [%] (95% CI)
GI AEs
All GI AEs 9.9 9.0 1.3 (1.1, 1.5) 2.1 (0.9, 3.3)
dyspepsiaa 1.8 1.4 1.7 (1.2, 2.4) 0.8 (0.2, 1.3)
Minor GI disordersb 5.0 4.5 1.2 (1.0, 1.5) 0.9 (0.0, 1.8)
abdominal painc 0.5 0.2 1.9 (0.9, 4.0) 0.2 (0.0, 0.5)
any dyspepsiac 5.3 4.6 1.3 (1.1, 1.6) 1.2 (0.3, 2.2)
minor dyspepsiac 5.0 4.0 1.4 (1.1, 1.8) 1.5 (0.6, 2.3)
severe dyspepsiac 0.6 0.9 0.7 (0.4, 1.2) -0.3 (-0.6, 0.1)
GERD-related symptomsc <0.1 <0.1 1.5 (0.3, 7.0) 0.03 (-0.09, 0.1)
Non-GI AEs
Headache 0.8 1.7 0.5 (0.3, 0.8) -0.7 (-1.2, -0.2)
Dizziness 0.9 1.1 0.9 (0.6, 1.3) -0.1 (-0.6, 0.3)
Tinnitus 0.2 0.1 1.7 (0.6, 4.5) 0.1 (-0.1, 0.3)
Sign of overdose 1.9 2.8 0.7 (0.6, 1.0) -0.6 (-1.3, 0.0)
Other bleeding (non-GI, non cerebral) 0.3 0.2 1.5 (0.6, 3.4) 0.1 (-0.1, 0.3)
Oral complicationsc 2.9 3.0 1.3 (0.97, 1.7) 0.6 (-0.1, 1.3)
a MedDRA term.
b Minor GI disorders include heartburn, nausea, vomiting and abdominal pain. Other terms are defined in table I.
c Combined term.
ASA arm =ASA alone or combined with additional therapy; GERD =gastroesophageal reflux disease; MedDRA =Medical Dictionary for
Regulatory Activities; OR = odds ratio; Placebo arm =placebo alone or combined with the additional therapy (pseudoephedrine, lidocaine, or
dextromethorphan).
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data we report here are valid for typical OTC
ASA use in the general population. According to
some surveys on consumer use of analgesics,[3,22]
92.4% of ASA users take one to two tablets
(500mg tablet equivalent) in a 4-week period.
Ourmeta-analysis agrees with two other studies
reported by Edwards et al.,[23] and Steiner and
Voelker.[24] The former study was not a pooled
analysis of individual patient data and was just
focused on the efficacy of single-dose ASA for the
relief of postoperative pain. Nevertheless, they
found risks of AEs with ASA use (13%) and pla-
cebo (11%) similar to those reported here. They
also found a significantly higher incidence of
drowsiness and what they describe as ‘gastric irri-
tation,’ with ASA 600–650mg than with placebo.
The latter study[24] used pooled individual pa-
tient data from 1581 patients treated with ASA
and 1271 patients treated with placebo in nine
randomized, double-blind, placebo-controlled clin-
ical trials, and these were included in our study.
They were chosen because all patients used single
doses of ASA 1000mg for the treatment of acute
migraine attacks, episodic tension-type headache,
and dental pain. The reported AE rates for ASA
and placebo were 14.9% and 11.1%, respectively;
this included 5.9% of patients experiencing GI
events with ASA and 3.5% experiencing them
with placebo. One additional study[11] reported
side effects arising from ASA, acetaminophen,
codeine, or placebo therapy in a retrospective
analysis of 54 single-dose, double-blind studies
involving 4346 patients with postsurgical dental
pain. Both the overall and the GI AEs were low
for all treatments, but codeine was associated with
a higher incidence of nausea, drowsiness, and
dizziness than acetaminophen, ASA, or placebo.
Available observational studies reporting on
the GI safety of non-cardiovascular ASA, taken
for the treatment of pain, fever, or colds, indicate
that its use is associated with an increased risk of
major GI complications, similar to other non-
selective NSAIDs.[6-8] In contrast, in our data and
in those of Edwards et al.,[23] no serious GI com-
plications were associated with ASA use or active
comparators. This should not necessarily be seen
as contradictory, since it is reasonable to assume
that the populations and type of drug use studied
are different. Clinical trials usually exclude pa-
tients with known GI risk factors, whereas obser-
vational studies include patients with various
levels of risk. This meta-analysis probably included
a population that was healthier and younger than
that reported in observational studies. Further-
more, it is possible that observational studies report
on patients with longer exposure to ASA use,
whereas our study basically applies to those tak-
ing a single tablet or using ASA doses no higher
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Fig. 3. Frequencies of patients who reported at least one adverse event (AE) of interest (all and drug related) with acetylsalicylic acid (ASA
[aspirin]) or with placebo. ADR = adverse drug reaction; GI= gastrointestinal; PT = preferred term; SOC = system organ class.
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than 1000mg/day for the relief of pain, fever, or
colds. The same considerations may apply to the
absence of GI bleeding events with ibuprofen in
this study, where the doses used were low (200–
400mg/day).
ASA use has been associated with other non-
GI AEs, both serious and less serious.[11,25,26] No
cases of serious non-GI AEs were reported and
no significant differences were found between
ASA and placebo or between ASA and ibuprofen
or acetaminophen for less-serious non-GI AEs in
this meta-analysis.
We did not find statistically significant het-
erogeneity in the ORs in our analysis, suggesting
that these statistics are probably generalizable, at
least to the sort of patient included in the studies.
However, as might be expected with relatively
constant ORs and differing background rates of
AEs, there was heterogeneity in the risk differences.
This finding suggests that the risk differences can-
not be directly applied in other clinical contexts.
The data presented in this study have several
limitations. The way ASA is used may vary among
different populations and therefore the data re-
ported may not be applicable to them. The report
from Curhan et al.[2] from the Nurses’ Health
Study showed that ASA was used daily by 25.4%
of women >51 years of age, and that 40.1% used
ASA ‡1 day/week. Since it is now widely known
that ASA protects against cardiovascular events
and colon cancer,[1,27] some may take this com-
pound very often or on a daily basis for these pur-
poses. In any case, multiple-day exposure to ASA
is not uncommon in clinical practice, and the data
provided here, although focused on short-term
use of ASA for the treatment of acute pain, fever,
or colds, suggest an increased risk of AEs with
increasing dose and multiple doses.
Another limitation of this study is that the
safety data reported here may not be valid for the
entire population with access to OTC ASA for
the relief of pain, fever, or colds. The risk factors
for GI complications in NSAID and ASA users
are well defined and include older age (>65 years
old), patients with ulcer history, and patients with
concomitant use of otherNSAIDs, corticosteroids,
Table IV. Adverse events (AEs) with acetylsalicylic acid (ASA [aspirin]) in monotherapy compared with active comparators (acetaminophen
[paracetamol] and ibuprofen)
Event ASA [%]
(n =1128)
Acetaminophen [%]
(n = 1145)
OR (95% CI) ASA [%]
(n= 707)
Ibuprofen [%]
(n =754)
OR (95% CI)
GI AEs 10.4 10.1 1.0 (0.8, 1.4) 3.5 2.3 1.4 (0.8, 2.7)
dyspepsiaa 4.0 2.5 1.7 (1.0, 2.8) 0.1 0.4 0.3 (0.0, 2.9)
Minor GI disordersb 6.8 7.2 0.9 (0.7, 1.3) 3.4 1.9 1.7 (0.9, 3.3)
abdominal painc 0.3 <0.1 2.5 (0.3, 18.7) 0.3 0.3 1.0 (0.1, 6.4)
any dyspepsiac 7.9 7.6 1.0 (0.7, 1.4) 2.7 1.6 1.5 (0.7, 3.2)
minor dyspepsiac 7.6 7.2 1.1 (0.8, 1.5) 2.5 1.3 1.8 (0.8, 3.9)
severe dyspepsiac 0.7 0.9 0.8 (0.3, 2.6) 0.4 0.3 1.4 (0.2, 7.8)
Headache 1.0 1.5 0.6 (0.3, 1.49) 0.7 0.7 1.0 (0.3, 3.4)
Dizziness 1.5 2.0 0.8 (0.4, 1.4) 0.4 0.9 0.5 (0.1, 2.1)
Tinnitus <0.1 0.0 NA 0.3 0.0 NA
Sign of overdose 2.6 3.5 0.7 (0.4, 1.2) 1.4 1.7 0.8 (0.3, 2.0)
Other bleeding (non-GI,
non cerebral)
<0.1 0.2 NA 0.1 0.0 NA
Oral complicationsc 0.2 0.8 0.2 (0.1, 1.1) 0.1 0.1 1.0 (0.1, 12.2)
a MedDRA term.
b Minor GI disorders include heartburn, nausea, vomiting and abdominal pain. Other terms are defined in table I.
c Combined term.
ASA arm =ASA alone or combined with additional therapy; GI =gastrointestinal; MedDRA =Medical Dictionary for Regulatory Activities;
NA= not available; OR = odds ratio; placebo arm = placebo alone or combined with the additional therapy (pseudoephedrine, lidocaine or
dextromethorphan).
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or anticoagulants. Patients at risk (elderly pa-
tients or those with an ulcer history) were ex-
cluded in these clinical trials.
Finally, the very low incidence of serious AEs
in our study population limited our ability to in-
vestigate differences between ASA and placebo
or other comparators in this regard. Much larger
studies would be required to generate enough
events to make such an analysis feasible.
Conclusion
In conclusion, this meta-analysis of clinical
trials of short-term ASA, mostly single dose and of
1-day duration, used for the treatment of pain, fe-
ver, or colds at common OTC doses, has shown a
low incidence of AEs. There was a small increase in
the risk of mild to moderate dyspepsia and ab-
dominal pain with ASA, but no significant occur-
rence of major GI complications was observed.
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